Esperion Stock Soars 19.88% Despite Q4 Loss

On March 28, 2025, Esperion's stock price surged by 19.88% in pre-market trading, indicating a significant bullish sentiment among investors.

Esperion Therapeutics recently reported a Q4 loss, falling short of revenue estimates. This financial performance has raised concerns among investors about the company's short-term prospects. Despite the setback, HC Wainwright reaffirmed a "buy" rating and set a target price of $16.00 per share, suggesting confidence in the company's long-term potential.

Looking ahead, Esperion Therapeutics is expected to release its next earnings report on May 6, 2025. Analysts anticipate a loss of $0.18 per share, which could influence investor sentiment and stock performance in the coming weeks. The company's short interest stands at 28.90 million shares, representing 14.87% of the float, indicating a notable level of bearish sentiment among traders.